10-Q: Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Tenax Therapeutics reported a net loss of $3.8 million for the first quarter of 2024, while advancing its Phase 3 trial for oral levosimendan.

Summary

• Tenax Therapeutics reported a net loss of $3.8 million for the first quarter of 2024, compared to a net loss of $1.4 million for the same period in 2023.
• The company's operating expenses increased to $3.9 million, primarily due to a significant rise in research and development costs to $2.7 million.
• General and administrative expenses were $1.2 million, slightly down from $1.3 million in the prior year.
• The company's cash and cash equivalents increased to $12.5 million as of March 31, 2024, up from $9.8 million at the end of 2023.
• Tenax is prioritizing its Phase 3 LEVEL trial for oral levosimendan and has suspended plans for an imatinib Phase 3 trial.
• The company believes it has sufficient capital to fund operations through calendar year 2024, but will need additional financing beyond that period.
• The company completed a public offering in February 2024, raising approximately $8.0 million in net proceeds.
• The company has been granted additional patents related to levosimendan, including one covering all therapeutic doses of all three formulations of the product in patients with PH-HFpEF.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While the company has made progress in its clinical trials and secured additional funding, the increased losses, the need for substantial future financing, and the going concern warning temper the positive aspects. The sentiment is cautiously negative.

Positives

• The company's cash position improved to $12.5 million, providing funding through 2024.
• The company successfully raised $8.0 million through a public offering in February 2024.
• The company has been granted additional patents related to levosimendan, strengthening its intellectual property portfolio.
• The company is actively progressing its Phase 3 LEVEL trial for oral levosimendan, a key strategic priority.
• The company has global rights to oral and subcutaneous formulations of levosimendan used in the treatment of pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF).

Negatives

• The company reported a net loss of $3.8 million for the first quarter of 2024.
• Operating expenses increased significantly, primarily due to higher research and development costs.
• The company has an accumulated deficit of approximately $301.1 million.
• The company will need substantial additional financing beyond 2024.
• There is substantial doubt about the company's ability to continue as a going concern.

Risks

• The company has incurred significant losses since inception and expects to continue to incur losses for the foreseeable future.
• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company's clinical trials are subject to risks and uncertainties, including enrollment challenges and regulatory hurdles.
• The company may need to relinquish rights to its technologies or product candidates if it raises additional funds through collaboration and licensing arrangements.
• The company's future capital requirements are subject to many factors, including the progress of clinical trials, regulatory approvals, and the cost of commercialization.

Future Outlook

The company believes it has sufficient capital to fund its planned operations through calendar year 2024, but will need substantial additional financing beyond such period. The company intends to submit marketing authorization applications following two Phase 3 trials of levosimendan and, when appropriate, a single Phase 3 trial of imatinib.

Management Comments

• Management believes the accompanying unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP), which contemplate continuation of the Company as a going concern.
• Management is actively seeking additional sources of equity and/or debt financing; however, there is no assurance that any additional funding will be available.
• Management has implemented certain cost-cutting measures and is actively exploring a diverse range of strategic options to help drive stockholder value.
• The company has elected to prioritize its LEVEL trial (Phase 3 testing of oral levosimendan), ahead of imatinib.

Industry Context

The company is operating in the biopharmaceutical industry, focusing on developing treatments for pulmonary hypertension. The company's focus on levosimendan for PH-HFpEF addresses a significant unmet medical need, as there are currently no approved pharmaceutical therapies for this condition. The company's strategy of leveraging existing drugs with new formulations and indications is a common approach in the industry to reduce development risk and time.

Comparison to Industry Standards

• Tenax's increased R&D spending in Q1 2024 is typical for a biotech company advancing a Phase 3 trial, similar to companies like Arena Pharmaceuticals (acquired by Pfizer) during their late-stage development of etrasimod.
• The company's cash burn rate of approximately $5.2 million in Q1 2024 is within the range of other clinical-stage biotech companies, such as Corvus Pharmaceuticals, which also have ongoing Phase 3 trials.
• The company's reliance on equity financing is common for biotech companies, but the need for substantial additional capital beyond 2024 highlights the financial risks, similar to companies like Agenus, which frequently raise capital to fund their clinical programs.
• The company's focus on repurposing existing drugs like levosimendan and imatinib is a strategy employed by companies like Biohaven Pharmaceuticals, which has successfully developed new uses for existing drugs.
• The company's intellectual property strategy, including the recent patents for levosimendan, is crucial for maintaining a competitive advantage, similar to companies like Vertex Pharmaceuticals, which heavily rely on patent protection for their therapies.

Stakeholder Impact

• Shareholders face potential dilution from future equity offerings.
• Employees may be impacted by cost-cutting measures or changes in the company's strategic direction.
• Patients with PH-HFpEF may benefit from the development of levosimendan.
• Creditors face increased risk due to the company's going concern status.

Next Steps

• The company will continue to enroll patients in the Phase 3 LEVEL trial for oral levosimendan.
• The company will seek additional financing to fund operations beyond 2024.
• The company will continue to explore strategic options to enhance stockholder value.
• The company intends to submit marketing authorization applications following two Phase 3 trials of levosimendan and, when appropriate, a single Phase 3 trial of imatinib.

Key Dates

Keywords

levosimendan, pulmonary hypertension, PH-HFpEF, clinical trial, Phase 3, imatinib, biopharmaceutical, patents, financing, research and development